HTA14 Expanding the HTA Cost-Effectiveness Analyses for CheckMate 9LA: Nivolumab Plus Ipilimumab Plus Chemotherapy As First-Line Strategy for Non-Small Cell Lung Cancer
Abstract
Authors
I. Orsini M. Venkatachalam Y. Yuan A. Lee J.R. Penrod